BHC — Bausch Health Companies Inc. stock price, charts and financials

QT69Bausch Health Companies Inc.

Bausch Health Companies Inc. (NYSE: BHC) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
5.67
+0.02+0.35%
BHCQT69Bausch Health Companies Inc.·NYSE
5.67+0.35%
TA
Loading chart...
Screen all →
Snapshot
Index-P/E-EPS (ttm)-2.95Insider Own46.63%Shs Outstand373.99MPerf Week-3.24%
Market Cap2.12BForward P/E1.30EPS next Y4.37Insider Trans-0.04%Shs Float331.22MPerf Month-17.71%
Enterprise Value21.07BPEG0.00EPS next Q1.27Inst Own-Short Float2.48%Perf Quarter18.87%
Income-1.10BP/S0.20EPS this Y255.38%Inst Trans-Short Ratio2.33Perf Half Y12.72%
Sales10.85BP/B-EPS next Y-4.60%ROA-4.43%Short Interest8.22MPerf YTD-18.42%
Book/sh-P/C1.18EPS next 5Y-6.11%ROE88.77%52W High8.00 -29.12%Perf Year-16.98%
Cash/sh-P/FCF1.52EPS past 3/5Y-ROIC13.07%52W Low4.33 30.95%Perf 3Y-34.30%
Dividend Est.-EV/EBITDA10.30Sales past 3/5Y8.11% 5.04%Gross Margin71.82%Volatility3.32% 4.18%Perf 5Y-80.07%
Dividend TTM-EV/Sales1.94EPS Y/Y TTM-2169.23%Oper. Margin25.44%ATR (14)0.28Perf 10Y-81.07%
Dividend Ex-DateNov 10, 2010Quick Ratio1.08Sales Y/Y TTM12.76%Profit Margin-10.12%RSI (14)38.99Recom2.61
Dividend Gr. 3/5Y-13.82% 20.68%Current Ratio1.44EPS Q/Q40.00%SMA20-9.35%Beta0.36Target Price9.83
Payout0.00%Debt/Eq-Sales Q/Q12.73%SMA50-3.61%Rel Volume0.52Prev Close5.65
Employees20,300LT Debt/Eq55.61EarningsOct 28SMA200-2.89%Avg Volume3.58MPrice5.67
IPO DateMar 29, 1994Option/ShortYes / YesEPS/Sales Surpr.28.41% 8.74%Net Debt/EBITDA9.26Volume1,854,315Change0.35%
Analyst Ratings
DateActionAnalystRatingTarget
Jan-07-26ReiteratedTruist SecuritiesHold$7.00$8.00
Dec-08-25InitiatedBarclaysEqual Weight$8.00
Feb-06-25DowngradeJefferiesBuyHold
Oct-23-24ReiteratedRBC CapitalSector Perform$8.50$10
Aug-02-24DowngradePiper SandlerNeutralUnderweight
Jul-25-24ReiteratedTruist SecuritiesHold$7.00
Jul-10-24InitiatedRaymond JamesMarket Perform on Xifaxan risk$8.00
Apr-29-24ReiteratedPiper SandlerNeutral$6.00$9.00
Apr-23-24ReiteratedRBC CapitalSector Perform$12$11
Apr-11-24ReiteratedJefferiesBuy$16
Latest News· Times ET
Sep-17-26
Sep-16-26
Sep-14-26
Sep-08-26
Sep-01-26
Aug-27-26
Aug-24-26
Aug-21-26
Aug-20-26
Aug-17-26
Aug-12-26
Aug-11-26
Aug-11-2602:06PM
Company

Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta's medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S. The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018. Its corporate headquarters are located in Laval, Canada.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue10,85310,2669,625
Cost of Goods Sold Incl. D&A3,0583,0132,782
Gross Profit7,7957,2536,843
Selling, General and Administrative Excl. Other3,4453,4383,283
Research and Development634629634
Other Operating Expense9551,0011,380
Operating Income2,7612,1851,546
Interest Expense1,6071,6041,388
Unusual Expense
Non-Operating Income (Expense)-1,886-2149
Net Income Before Taxes-732367167
Income Taxes361247239
Consolidated Net Income-1,098157-46
Net Income From Continuing Operations-1,093120-72
Net Income-1,098157-46
EPS (Recurring)-2.950.43-0.13
EPS (Basic, Before Extraordinaries)-2.950.43-0.13
EPS (Diluted)-2.950.43-0.13
EBITDA2,0473,1793,134
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio16.16
Price To Sales Ratio0.200.250.31
Gross Margin71.8270.6571.10
Operating Margin25.4421.2816.06
Net Margin-10.121.53-0.48
Shares Outstanding375371368
Market Capitalization2,1262,5782,966
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$8.93$7.66$6.38$5.11$3.84 Close Price0.00M3.91M7.81M11.72M15.63MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Lenar Aimee J.President, US PharmaAug 19 '26Sale7.0336,827258,894334,853Aug 20
Lee Frank D.DirectorMay 19 '26Sale5.4324,456132,79649,339May 20
Carson SeanaEVP, General CounselMar 03 '26Sale5.774,42025,503616,761Mar 03
Carson SeanaEVP, General CounselMar 02 '26Sale5.786,85639,628776,076Mar 03
Carson SeanaEVP, General CounselFeb 27 '26Sale5.958,38849,909809,258Feb 27
PAULSON & CO. INC.10% OwnerNov 25 '25Buy6.252,500,00015,625,00073,255,869Nov 28
Carson SeanaEVP, General CounselSep 08 '25Sale7.3113,37097,735499,585Sep 08
Lee Frank D.DirectorAug 21 '25Sale7.6615,912121,88673,795Aug 22
Paulson JohnDirectorAug 14 '25Buy9.0034,721,118312,490,06270,755,869Aug 14
Paulson JohnDirectorAug 13 '25Buy7.0686,409610,04836,034,751Aug 13
Paulson JohnDirectorAug 12 '25Buy6.881,156,6407,957,68335,948,342Aug 13
Paulson JohnDirectorAug 11 '25Buy6.352,000,00012,700,00034,791,702Aug 13
Paulson JohnDirectorJun 13 '25Buy5.943,564,05921,170,51032,791,702Jun 17
Paulson JohnDirectorJun 12 '25Buy5.471,005,3765,499,40729,227,643Jun 12
Paulson JohnDirectorJun 11 '25Buy5.241,029,0985,392,47428,222,267Jun 12
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.